Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC) is the second most lethal malignancy globally and is increasing in incidence in the United States. Unfortunately, there are few effective systemic treatment options, particularly for disseminated disease. Glypican-3 (GPC3) is a proteoglycan cell surface receptor overexpressed in most HCCs and provides a unique target for molecular therapies. We have previously demonstrated that PET imaging using a 89Zr-conjugated monoclonal anti-GPC3 antibody (αGPC3) can bind to minute tumors and allow imaging with high sensitivity and specificity in an orthotopic xenograft mouse model of HCC and that serum alpha-fetoprotein (AFP) levels are highly correlated with tumor size in this model. In the present study, we conjugated 90Y, a high-energy beta-particle-emitting radionuclide, to our αGPC3 antibody to develop a novel antibody-directed radiotherapeutic approach for HCC. Luciferase-expressing HepG2 human hepatoblastoma cells were orthotopically implanted in the livers of athymic nude mice, and tumor establishment was verified at 6 weeks after implantation by bioluminescent imaging and serum AFP concentration. Tumor burden by bioluminescence and serum AFP concentration was highly correlated in our model. Yttrium-90 was conjugated to αGPC3 using the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and injected via the tail vein into the experimental mice at a dose of 200 μCi/mouse ormore »
- Authors:
-
- Univ. of Washington, Seattle, WA (United States)
- Publication Date:
- Research Org.:
- Univ. of Washington, Seattle, WA (United States)
- Sponsoring Org.:
- USDOE Office of Science (SC)
- OSTI Identifier:
- 1611807
- Grant/Contract Number:
- SC0012445
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Journal of Oncology
- Additional Journal Information:
- Journal Volume: 2019; Journal ID: ISSN 1687-8450
- Publisher:
- Hindawi
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 60 APPLIED LIFE SCIENCES; Oncology
Citation Formats
Ludwig, Andrew D., Labadie, Kevin P., Seo, Y. David, Hamlin, Donald K., Nguyen, Holly M., Mahadev, Vimukta M., Yeung, Raymond S., Wilbur, D. S., and Park, James O. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. United States: N. p., 2019.
Web. doi:10.1155/2019/4564707.
Ludwig, Andrew D., Labadie, Kevin P., Seo, Y. David, Hamlin, Donald K., Nguyen, Holly M., Mahadev, Vimukta M., Yeung, Raymond S., Wilbur, D. S., & Park, James O. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. United States. https://doi.org/10.1155/2019/4564707
Ludwig, Andrew D., Labadie, Kevin P., Seo, Y. David, Hamlin, Donald K., Nguyen, Holly M., Mahadev, Vimukta M., Yeung, Raymond S., Wilbur, D. S., and Park, James O. Sun .
"Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma". United States. https://doi.org/10.1155/2019/4564707. https://www.osti.gov/servlets/purl/1611807.
@article{osti_1611807,
title = {Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma},
author = {Ludwig, Andrew D. and Labadie, Kevin P. and Seo, Y. David and Hamlin, Donald K. and Nguyen, Holly M. and Mahadev, Vimukta M. and Yeung, Raymond S. and Wilbur, D. S. and Park, James O.},
abstractNote = {Hepatocellular carcinoma (HCC) is the second most lethal malignancy globally and is increasing in incidence in the United States. Unfortunately, there are few effective systemic treatment options, particularly for disseminated disease. Glypican-3 (GPC3) is a proteoglycan cell surface receptor overexpressed in most HCCs and provides a unique target for molecular therapies. We have previously demonstrated that PET imaging using a 89Zr-conjugated monoclonal anti-GPC3 antibody (αGPC3) can bind to minute tumors and allow imaging with high sensitivity and specificity in an orthotopic xenograft mouse model of HCC and that serum alpha-fetoprotein (AFP) levels are highly correlated with tumor size in this model. In the present study, we conjugated 90Y, a high-energy beta-particle-emitting radionuclide, to our αGPC3 antibody to develop a novel antibody-directed radiotherapeutic approach for HCC. Luciferase-expressing HepG2 human hepatoblastoma cells were orthotopically implanted in the livers of athymic nude mice, and tumor establishment was verified at 6 weeks after implantation by bioluminescent imaging and serum AFP concentration. Tumor burden by bioluminescence and serum AFP concentration was highly correlated in our model. Yttrium-90 was conjugated to αGPC3 using the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and injected via the tail vein into the experimental mice at a dose of 200 μCi/mouse or 300 μCi/mouse. Control mice received DOTA-αGPC3 without radionuclide. At 30 days after a single dose of the radioimmunotherapy agent, mean serum AFP levels in control animals increased dramatically, while animals treated with 200 μCi only experienced a minor increase, indicating cessation of tumor growth, and animals treated with 300 μCi experienced a reduction in serum AFP concentration, indicating tumor shrinkage. Mean tumor-bearing liver weight in control animals was also significantly greater than that in animals that received either dose of 90Y-αGPC3. These results were achieved without significant toxicity as measured by body condition scoring and body weight. The results of this preclinical pilot demonstrate that GPC3 can be used as a target for radioimmunotherapy in an orthotopic mouse model of HCC and may be a target of clinical significance, particularly for disseminated HCC.},
doi = {10.1155/2019/4564707},
journal = {Journal of Oncology},
number = ,
volume = 2019,
place = {United States},
year = {Sun Sep 15 00:00:00 EDT 2019},
month = {Sun Sep 15 00:00:00 EDT 2019}
}
Web of Science
Works referenced in this record:
Glypican-3 Inhibits Hedgehog Signaling during Development by Competing with Patched for Hedgehog Binding
journal, May 2008
- Capurro, Mariana I.; Xu, Ping; Shi, Wen
- Developmental Cell, Vol. 14, Issue 5
Glypican-3-Targeted 89Zr PET Imaging of Hepatocellular Carcinoma
journal, March 2014
- Sham, J. G.; Kievit, F. M.; Grierson, J. R.
- Journal of Nuclear Medicine, Vol. 55, Issue 5
Bioluminescence Imaging Correlates with Tumor Serum Marker, Organ Weights, Histology, and Human DNA Levels during Treatment of Orthotopic Tumor Xenografts with Antibodies
journal, April 2012
- Poeschinger, Thomas; Renner, Anja; Weber, Thomas
- Molecular Imaging and Biology, Vol. 15, Issue 1
Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma
journal, February 2007
- Jia, H. -L.; Ye, Q. -H.; Qin, L. -X.
- Clinical Cancer Research, Vol. 13, Issue 4
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
journal, May 2005
- Yamauchi, Naoko; Watanabe, Akira; Hishinuma, Michiyo
- Modern Pathology, Vol. 18, Issue 12
Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome
journal, March 1996
- Pilia, Giuseppe; Hughes-Benzie, Rhiannon M.; MacKenzie, Alex
- Nature Genetics, Vol. 12, Issue 3
90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study
journal, March 2015
- Chevallier, Patrice; Eugene, Thomas; Robillard, Nelly
- The Lancet Haematology, Vol. 2, Issue 3
Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
journal, September 2016
- Kaseb, Ahmed Omar; Hassan, Manal; Lacin, Sahin
- Oncotarget, Vol. 7, Issue 43
Diagnosis of hepatocellular carcinoma
journal, March 2005
- Bialecki, Eldad S.; Di Bisceglie, Adrian M.
- HPB, Vol. 7, Issue 1
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
journal, January 2016
- Haruyama, Yukihiro
- World Journal of Gastroenterology, Vol. 22, Issue 1
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
journal, December 2016
- Salem, Riad; Gordon, Andrew C.; Mouli, Samdeep
- Gastroenterology, Vol. 151, Issue 6
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
journal, January 2019
- Saini, Aman; Wallace, Alex; Alzubaidi, Sadeer
- Journal of Clinical Medicine, Vol. 8, Issue 1
Treatment of Inoperable Primary Pancreatic and Liver Cancer by the Intra-Arterial Administration of Radioactive Isotopes (Y Radiating Microspheres)
journal, January 1965
- Ariel, Irving M.
- Annals of Surgery, Vol. 162, Issue 2
A rapid, simple, and humane method for submandibular bleeding of mice using a lancet
journal, October 2005
- Golde, William T.; Gollobin, Peter; Rodriguez, Luis L.
- Lab Animal, Vol. 34, Issue 9
Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis
journal, October 2014
- Jia, Xiaobo; Liu, Jiao; Gao, Yingtang
- Archives of Medical Research, Vol. 45, Issue 7
Glypican-3-Targeting F(ab')2 for 89Zr PET of Hepatocellular Carcinoma
journal, October 2014
- Sham, J. G.; Kievit, F. M.; Grierson, J. R.
- Journal of Nuclear Medicine, Vol. 55, Issue 12
A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma
journal, December 2017
- Woodfield, Sarah E.; Shi, Yan; Patel, Roma H.
- Scientific Reports, Vol. 7, Issue 1
Fractionated radioimmunotherapy with 90 Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
journal, May 2012
- Ocean, Allyson J.; Pennington, Kenneth L.; Guarino, Michael J.
- Cancer, Vol. 118, Issue 22
Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma
journal, June 2016
- Wang, Li; Pan, Liuhong; Yao, Min
- Oncotarget, Vol. 7, Issue 27
Induction of Remission in Hepatocellular Carcinoma with Doxorubicin
journal, May 1978
- Johnson, P. J.; Thomas, Howard; Williams, Roger
- The Lancet, Vol. 311, Issue 8072
Global cancer statistics, 2012: Global Cancer Statistics, 2012
journal, February 2015
- Torre, Lindsey A.; Bray, Freddie; Siegel, Rebecca L.
- CA: A Cancer Journal for Clinicians, Vol. 65, Issue 2
Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric field
journal, November 2020
- Liu, Jianpeng; Chen, Xinhua; Zheng, Shusen
- Frontiers of Medicine, Vol. 15, Issue 2
Diagnosis of hepatocellular carcinoma
journal, July 2014
- Cartier, V.; Aubé, C.
- Diagnostic and Interventional Imaging, Vol. 95, Issue 7-8
Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
text, January 2012
- Nathan, Hall,; H., O'Neil, Bert; Timothy, Manzone,
- The University of North Carolina at Chapel Hill University Libraries
Fractionated radioimmunotherapy with 90 Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
journal, May 2012
- Ocean, Allyson J.; Pennington, Kenneth L.; Guarino, Michael J.
- Cancer, Vol. 118, Issue 22
Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric field
journal, November 2020
- Liu, Jianpeng; Chen, Xinhua; Zheng, Shusen
- Frontiers of Medicine, Vol. 15, Issue 2
Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis
journal, October 2014
- Jia, Xiaobo; Liu, Jiao; Gao, Yingtang
- Archives of Medical Research, Vol. 45, Issue 7
Glypican-3 Inhibits Hedgehog Signaling during Development by Competing with Patched for Hedgehog Binding
journal, May 2008
- Capurro, Mariana I.; Xu, Ping; Shi, Wen
- Developmental Cell, Vol. 14, Issue 5
Major achievements in hepatocellular carcinoma
journal, February 2009
- Bruix, Jordi; Llovet, Josep M.
- The Lancet, Vol. 373, Issue 9664
Induction of Remission in Hepatocellular Carcinoma with Doxorubicin
journal, May 1978
- Johnson, P. J.; Thomas, Howard; Williams, Roger
- The Lancet, Vol. 311, Issue 8072
Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
journal, January 2017
- Kraeber-Bodere, Françoise; Pallardy, Amandine; Maisonneuve, Hervé
- The Lancet Haematology, Vol. 4, Issue 1
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
journal, May 2005
- Yamauchi, Naoko; Watanabe, Akira; Hishinuma, Michiyo
- Modern Pathology, Vol. 18, Issue 12
Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome
journal, March 1996
- Pilia, Giuseppe; Hughes-Benzie, Rhiannon M.; MacKenzie, Alex
- Nature Genetics, Vol. 12, Issue 3
A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma
journal, December 2017
- Woodfield, Sarah E.; Shi, Yan; Patel, Roma H.
- Scientific Reports, Vol. 7, Issue 1
Diagnosis of hepatocellular carcinoma
journal, March 2005
- Bialecki, Eldad S.; Di Bisceglie, Adrian M.
- HPB, Vol. 7, Issue 1
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
journal, July 2005
- Capurro, Mariana I.; Xiang, Yun-Yan; Lobe, Corrinne
- Cancer Research, Vol. 65, Issue 14
Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
journal, December 2008
- Ishiguro, T.; Sugimoto, M.; Kinoshita, Y.
- Cancer Research, Vol. 68, Issue 23
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
journal, January 2013
- Zhu, A. X.; Gold, P. J.; El-Khoueiry, A. B.
- Clinical Cancer Research, Vol. 19, Issue 4
GPC-3 in hepatocellular carcinoma: current perspectives
journal, January 2016
- Wu, Yongle; Liu, Hui; Ding, Hui-Guo
- Journal of Hepatocellular Carcinoma, Vol. Volume 3
Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
journal, May 2014
- Nakatsura, Tetsuya; Ofuji, Kazuya; Saito, Keigo
- Journal of Hepatocellular Carcinoma
Glypican-3–Targeted 89Zr PET Imaging of Hepatocellular Carcinoma: Where Antibody Imaging Dares to Tread
journal, March 2014
- Marquez, Bernadette V.; Zheleznyak, Alexander; Lapi, Suzanne E.
- Journal of Nuclear Medicine, Vol. 55, Issue 5
Glypican-3-Targeting F(ab')2 for 89Zr PET of Hepatocellular Carcinoma
journal, October 2014
- Sham, J. G.; Kievit, F. M.; Grierson, J. R.
- Journal of Nuclear Medicine, Vol. 55, Issue 12
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
journal, January 2019
- Saini, Aman; Wallace, Alex; Alzubaidi, Sadeer
- Journal of Clinical Medicine, Vol. 8, Issue 1
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
journal, January 2016
- Haruyama, Yukihiro
- World Journal of Gastroenterology, Vol. 22, Issue 1